PMN

SEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · nonDerivative · entry 1

GORDON MICHAEL S · CIK 0001034608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Title 19 Promis

Disclosed balance after: 2,195,429

F1 · kind: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F1 · price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

SEC source: 0001104659-25-071857 · tm2521929-1_4seq1.xml · derivative · entry 6

Title 19 Promis · CIK 0002005531 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F3 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F3 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F3 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

SEC source: 0001104659-25-071857 · tm2521929-1_4seq1.xml · derivative · entry 5

Title 19 Promis · CIK 0002005531 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F2 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F2 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F2 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-25-071857 · tm2521929-1_4seq1.xml · derivative · entry 4

Title 19 Promis · CIK 0002005531 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F1 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F1 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F1 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-25-071857 · tm2521929-1_4seq1.xml · nonDerivative · entry 3

Title 19 Promis · CIK 0002005531 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,435,029

F3 · kind: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F3 · price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

SEC source: 0001104659-25-071857 · tm2521929-1_4seq1.xml · nonDerivative · entry 2

Title 19 Promis · CIK 0002005531 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,315,229

F2 · kind: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F2 · price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-25-071857 · tm2521929-1_4seq1.xml · nonDerivative · entry 1

Title 19 Promis · CIK 0002005531 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,195,429

F1 · kind: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F1 · price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-25-078631 · tm2523440-4_4aseq1.xml · derivative · entry 3

GORDON MICHAEL S · CIK 0001034608 · See Remarks section.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F2 · derivative.exercise_price: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

F5 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F5 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F5 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F3 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

SEC source: 0001104659-25-078631 · tm2523440-4_4aseq1.xml · derivative · entry 2

GORDON MICHAEL S · CIK 0001034608 · See Remarks section.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F2 · derivative.exercise_price: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

F4 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F4 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F4 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F3 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

SEC source: 0001104659-25-078631 · tm2523440-4_4aseq1.xml · derivative · entry 1

GORDON MICHAEL S · CIK 0001034608 · See Remarks section.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F1 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F2 · derivative.exercise_price: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

F1 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F1 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F3 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

SEC source: 0001104659-25-078637 · tm2523440-3_4aseq1.xml · derivative · entry 3

Title 19 Promis · CIK 0002005531 · See Remarks section.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F2 · derivative.exercise_price: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

F4 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F4 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F4 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

SEC source: 0001104659-25-078637 · tm2523440-3_4aseq1.xml · derivative · entry 2

Title 19 Promis · CIK 0002005531 · See Remarks section.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F2 · derivative.exercise_price: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

F3 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F3 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F3 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-25-078637 · tm2523440-3_4aseq1.xml · derivative · entry 1

Title 19 Promis · CIK 0002005531 · See Remarks section.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F1 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F2 · derivative.exercise_price: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

F1 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F1 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · derivative · entry 8

Sclar Jeremy M. · CIK 0001955608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 697,674 shares

Expires not disclosed

F4 · derivative.exercise_price: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F4 · derivative.exercise_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F4 · derivative.expiration_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

SEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · derivative · entry 7

Sclar Jeremy M. · CIK 0001955608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 697,674 shares

Expires not disclosed

F3 · derivative.exercise_price: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F3 · derivative.exercise_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F3 · derivative.expiration_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

SEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · derivative · entry 6

Sclar Jeremy M. · CIK 0001955608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 697,674 shares

Expires not disclosed

F1 · derivative.exercise_price: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F1 · derivative.exercise_date: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F1 · derivative.expiration_date: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

SEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · nonDerivative · entry 3

Sclar Jeremy M. · CIK 0001955608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By JS Trust

Disclosed balance after: 3,710,459

F4 · kind: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F4 · price: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

SEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · nonDerivative · entry 2

Sclar Jeremy M. · CIK 0001955608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By JS Trust

Disclosed balance after: 3,012,785

F3 · kind: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F3 · price: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

SEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · nonDerivative · entry 1

Sclar Jeremy M. · CIK 0001955608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Jeremy M. Sclar 2012 Irrevocable Family Trust

Disclosed balance after: 2,315,111

F1 · kind: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F1 · price: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

SEC source: 0001104659-25-095035 · tm2523607-3_4seq1.xml · derivative · entry 6

Jeremy M. Sclar 2012 Irrevocable Family Trust · CIK 0002089163 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 697,674 shares

Expires not disclosed

F3 · derivative.exercise_price: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F3 · derivative.exercise_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F3 · derivative.expiration_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

SEC source: 0001104659-25-095035 · tm2523607-3_4seq1.xml · derivative · entry 5

Jeremy M. Sclar 2012 Irrevocable Family Trust · CIK 0002089163 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 697,674 shares

Expires not disclosed

F2 · derivative.exercise_price: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F2 · derivative.exercise_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F2 · derivative.expiration_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

SEC source: 0001104659-25-095035 · tm2523607-3_4seq1.xml · derivative · entry 4

Jeremy M. Sclar 2012 Irrevocable Family Trust · CIK 0002089163 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 697,674 shares

Expires not disclosed

F1 · derivative.exercise_price: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F1 · derivative.exercise_date: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F1 · derivative.expiration_date: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

SEC source: 0001104659-25-095035 · tm2523607-3_4seq1.xml · nonDerivative · entry 3

Jeremy M. Sclar 2012 Irrevocable Family Trust · CIK 0002089163 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,710,459

F3 · kind: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F3 · price: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

SEC source: 0001104659-25-095035 · tm2523607-3_4seq1.xml · nonDerivative · entry 2

Jeremy M. Sclar 2012 Irrevocable Family Trust · CIK 0002089163 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,012,785

F2 · kind: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F2 · price: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

SEC source: 0001104659-25-095035 · tm2523607-3_4seq1.xml · nonDerivative · entry 1

Jeremy M. Sclar 2012 Irrevocable Family Trust · CIK 0002089163 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,315,111

F1 · kind: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

F1 · price: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

SEC source: 0001104659-25-065292 · tm2519639-1_4seq1.xml · nonDerivative · entry 1

GORDON MICHAEL S · CIK 0001034608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: On June 30, 2025, the reporting person contributed 93,223 shares of common stock of the Issuer held by the reporting person to Skye Peak Partners LLC, a Delaware limited liability company ("SPP"), in exchange for membership interests of SPP.

SEC source: 0001374339-25-000003 · primary_doc.xml · derivative · entry 1

WYMAN WILLIAM W · CIK 0001077644 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board.

SEC source: 0001374339-25-000006 · primary_doc.xml · derivative · entry 1

Mandel-Brehm Josh · CIK 0001927058 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board.

SEC source: 0001374339-25-000005 · primary_doc.xml · derivative · entry 1

Kirwin Patrick D. · CIK 0001927062 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board.

SEC source: 0001374339-25-000004 · primary_doc.xml · derivative · entry 1

Shafmaster Madge K. · CIK 0001927066 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board.

SEC source: 0001374339-25-000002 · primary_doc.xml · derivative · entry 1

Williams Eugene · CIK 0001927626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board.

SEC source: 0001104659-25-078615 · tm2523440-2_4seq1.xml · nonDerivative · entry 1

GORDON MICHAEL S · CIK 0001034608 · See Remarks section.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Title 19 Acies

Disclosed balance after: 0

F1 · kind: On March 13, 2025, the ownership of Title 19 Acies, a series of a Delaware limited liability company, was assigned to Skye Peak Partners LLC, a Delaware limited liability company ("SPP"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from the Reporting Person as sole manager to Emmett Gordon and Michael Youniss as managers, and the Reporting Person does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, the Reporting Person no longer has a pecuniary interest in shares of the Issuer held by Title 19 Acies.

F1 · price: On March 13, 2025, the ownership of Title 19 Acies, a series of a Delaware limited liability company, was assigned to Skye Peak Partners LLC, a Delaware limited liability company ("SPP"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from the Reporting Person as sole manager to Emmett Gordon and Michael Youniss as managers, and the Reporting Person does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, the Reporting Person no longer has a pecuniary interest in shares of the Issuer held by Title 19 Acies.

F2 · ownership.nature: By Title 19 Acies, of which the Reporting Person was the sole manager.

SEC source: 0001374339-25-000001 · primary_doc.xml · nonDerivative · entry 1

Cashman Neil · CIK 0001927064 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By his spouse

Disclosed balance after: 16,617

SEC source: 0001104659-24-121136 · tm2429073-4_4seq1.xml · derivative · entry 1

Milbury Max A. · CIK 0001927056 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Shares · 70,000 shares

Expires 2034-11-18

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on November 18, 2025, and the balance shall vest ratably over 36 months.

SEC source: 0001104659-24-121135 · tm2429073-3_4seq1.xml · derivative · entry 1

Kaplan Johanne · CIK 0001967717 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Shares · 175,000 shares

Expires 2034-11-18

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on November 18, 2025, and the balance shall vest ratably over 36 months.

SEC source: 0001104659-24-121133 · tm2429073-2_4seq1.xml · derivative · entry 1

Cashman Neil · CIK 0001927064 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Shares · 200,000 shares

Expires 2034-11-18

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on November 18, 2025, and the balance shall vest ratably over 36 months.

SEC source: 0001104659-24-121132 · tm2429073-1_4seq1.xml · derivative · entry 1

ALTSTIEL LARRY DOUGLAS · CIK 0001619444 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Shares · 175,000 shares

Expires 2034-11-18

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on November 18, 2025, and the balance shall vest ratably over 36 months.

SEC source: 0001374339-24-000004 · primary_doc.xml · derivative · entry 2

Warma Neil K · CIK 0001437911 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,842,739

Underlying: Common Shares · 490,338 shares

Expires 2034-10-08

F2 · derivative.exercise_date: Performance Award shall vest 25% on the date that the 10-day VWAP of the Common Shares on the Nasdaq Capital Market exceeds three times the exercise price, $3.45, with the remainder vesting ratably over the following thirty-six months

SEC source: 0001374339-24-000004 · primary_doc.xml · derivative · entry 1

Warma Neil K · CIK 0001437911 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,352,455

Underlying: Common Shares · 1,144,122 shares

Expires 2034-10-08

F1 · derivative.exercise_date: Initial Award is 25% vested upon grant with the remaining shares vesting ratably over thirty-six months

SEC source: 0001104659-24-106770 · tm2425760-5_4seq1.xml · derivative · entry 1

WYMAN WILLIAM W · CIK 0001077644 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Shares · 40,000 shares

Expires 2034-10-03

F1 · derivative.exercise_date: 33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001104659-24-106767 · tm2425760-2_4seq1.xml · derivative · entry 1

Mandel-Brehm Josh · CIK 0001927058 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Shares · 40,000 shares

Expires 2034-10-03

F1 · derivative.exercise_date: 33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001104659-24-106769 · tm2425760-4_4seq1.xml · derivative · entry 1

Williams Eugene · CIK 0001927626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Shares · 40,000 shares

Expires 2034-10-03

F1 · derivative.exercise_date: 33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001104659-24-106768 · tm2425760-3_4seq1.xml · derivative · entry 1

Shafmaster Madge K. · CIK 0001927066 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Shares · 40,000 shares

Expires 2034-10-03

F1 · derivative.exercise_date: 33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001104659-24-106766 · tm2425760-1_4seq1.xml · derivative · entry 1

Kirwin Patrick D. · CIK 0001927062 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Shares · 40,000 shares

Expires 2034-10-03

F1 · derivative.exercise_date: 33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001374339-24-000003 · primary_doc.xml · nonDerivative · entry 3

Shafmaster Madge K. · CIK 0001927066 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,333

SEC source: 0001374339-24-000003 · primary_doc.xml · nonDerivative · entry 2

Shafmaster Madge K. · CIK 0001927066 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,333

SEC source: 0001374339-24-000003 · primary_doc.xml · nonDerivative · entry 1

Shafmaster Madge K. · CIK 0001927066 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,333

SEC source: 0001104659-24-100976 · tm2424268-1_4seq1.xml · nonDerivative · entry 2

GORDON MICHAEL S · CIK 0001034608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,223

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions, with prices ranging from $1.37 to $1.40 for an average weighted purchase price of $1.40. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased in each transaction.

SEC source: 0001104659-24-100976 · tm2424268-1_4seq1.xml · nonDerivative · entry 1

GORDON MICHAEL S · CIK 0001034608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,931

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in forty-two separate transactions, with prices ranging from $1.1200 to $1.3700 for an average weighted purchase price of $1.2228 rounded to the nearest ten thousandth. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased in each transaction.

SEC source: 0001374339-24-000002 · primary_doc.xml · nonDerivative · entry 1

Kirwin Patrick D. · CIK 0001927062 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,983